Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Jun 23, 2021
Date Accepted: Sep 2, 2021
Date Submitted to PubMed: Sep 17, 2021

The final, peer-reviewed published version of this preprint can be found here:

International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study

Weber GM, Zhang HG, L'Yi S, Bonzel CL, Hong C, Avillach P, Gutiérrez-Sacristán A, Palmer NP, Tan AL, Wang X, Yuan W, Gehlenborg N, Alloni A, Amendola DF, Bellasi A, Bellazzi R, Beraghi M, Bucalo M, Chiovato L, Cho K, Dagliati A, Estiri H, Follett RW, García-Barrio N, Hanauer DA, Henderson DW, Ho YL, Holmes JH, Hutch MR, Kavuluru R, Kirchoff K, Klann JG, Krishnamurthy AK, Le TT, Liu M, Loh NHW, Lozano-Zahonero S, Luo Y, Maidlow S, Makoudjou A, Malovini A, Moal B, Morris M, Mowery DL, Murphy SN, Neuraz A, Ngiam KY, Okoshi MP, Omenn GS, Patel LP, Pedrera-Jiménez M, Prudente RA, Samayamuthu MJ, Sanz J, Schriver ER, Schubert P, Serrano-Balazote P, Tan BW, Tanni SE, Tibollo V, Visweswaran S, Wagholikar KB, Xia Z, Zoeller D, The Consortium For Clinical Characterization Of COVID-19 By EHR (4CE) , Kohane IS, Cai T, South AM, Brat GA

International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study

J Med Internet Res 2021;23(10):e31400

DOI: 10.2196/31400

PMID: 34533459

PMCID: 8510151

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study

  • Griffin M Weber; 
  • Harrison G Zhang; 
  • Sehi L'Yi; 
  • Clara-Lea Bonzel; 
  • Chuan Hong; 
  • Paul Avillach; 
  • Alba Gutiérrez-Sacristán; 
  • Nathan P Palmer; 
  • Amelia LM Tan; 
  • Xuan Wang; 
  • William Yuan; 
  • Nils Gehlenborg; 
  • Anna Alloni; 
  • Danilo F Amendola; 
  • Antonio Bellasi; 
  • Riccardo Bellazzi; 
  • Michele Beraghi; 
  • Mauro Bucalo; 
  • Luca Chiovato; 
  • Kelly Cho; 
  • Arianna Dagliati; 
  • Hossein Estiri; 
  • Robert W Follett; 
  • Noelia García-Barrio; 
  • David A Hanauer; 
  • Darren W Henderson; 
  • Yuk-Lam Ho; 
  • John H Holmes; 
  • Meghan R Hutch; 
  • Ramakanth Kavuluru; 
  • Katie Kirchoff; 
  • Jeffrey G Klann; 
  • Ashok K Krishnamurthy; 
  • Trang T Le; 
  • Molei Liu; 
  • Ne Hooi Will Loh; 
  • Sara Lozano-Zahonero; 
  • Yuan Luo; 
  • Sarah Maidlow; 
  • Adeline Makoudjou; 
  • Alberto Malovini; 
  • Bertrand Moal; 
  • Michele Morris; 
  • Danielle L Mowery; 
  • Shawn N Murphy; 
  • Antoine Neuraz; 
  • Kee Yuan Ngiam; 
  • Marina P Okoshi; 
  • Gilbert S Omenn; 
  • Lav P Patel; 
  • Miguel Pedrera-Jiménez; 
  • Robson A Prudente; 
  • Malarkodi J Samayamuthu; 
  • Javier Sanz; 
  • Emily R Schriver; 
  • Petra Schubert; 
  • Pablo Serrano-Balazote; 
  • Byorn WL Tan; 
  • Suzana E Tanni; 
  • Valentina Tibollo; 
  • Shyam Visweswaran; 
  • Kavishwar B Wagholikar; 
  • Zongqi Xia; 
  • Daniela Zoeller; 
  • The Consortium For Clinical Characterization Of COVID-19 By EHR (4CE); 
  • Isaac S Kohane; 
  • Tianxi Cai; 
  • Andrew M South; 
  • Gabriel A Brat

ABSTRACT

Background:

Many countries have experienced two predominant waves of COVID-19-related hospitalizations. Comparing the clinical trajectories of patients hospitalized in separate waves of the pandemic enables further understanding of the evolving epidemiology, pathophysiology, and healthcare dynamics of the COVID-19 pandemic.

Objective:

In this retrospective cohort study, we analyzed electronic health record (EHR) data from patients with SARS-CoV-2 infections hospitalized in participating healthcare systems representing 315 hospitals across six countries. We compared hospitalization rates, severe COVID-19 risk, and mean laboratory values between patients hospitalized during the first and second waves of the pandemic.

Methods:

Using a federated approach, each participating healthcare system extracted patient-level clinical data on their first and second wave cohorts and submitted aggregated data to the central site. Data quality control steps were performed at the central site to correct for implausible values and harmonize units. Statistical analyses were performed by computing individual healthcare system effect sizes and synthesizing these using random effects meta-analyses to account for heterogeneity. We focused the laboratory analysis on C-reactive protein (CRP), ferritin, fibrinogen, procalcitonin, D-dimer, and creatinine based on their reported associations with severe COVID-19.

Results:

Data were available for 79,487 patients, of which 32,452 were hospitalized in the first wave and 47,035 in the second wave. The prevalence of male patients and patients aged 50–69 decreased significantly between the first and second wave. Patients hospitalized in the second wave had a 9.6% reduction in risk of severe COVID-19 compared to patients hospitalized in the first wave (95% CI: 8.2–11.1%). Demographic subgroup analyses indicated that patients aged 26–49; male and female patients; and Black patients had significantly lower risk for severe disease in the second wave compared to the first wave. At admission, the mean values of CRP were significantly lower in the second wave compared to the first. On the seventh hospital day, mean values of CRP, ferritin, fibrinogen, procalcitonin, and creatinine were significantly lower in the second wave compared to the first. In general, countries exhibited variable changes in laboratory testing rates from the first to the second wave. At admission, there was a significantly higher testing rate for D-dimer in France, Germany, and Spain.

Conclusions:

Patients hospitalized in the second wave were at significantly lower risk for severe COVID-19. This corresponded to mean laboratory values in the second wave that were more likely to be in typical physiological ranges on the seventh hospital day compared to the first wave. Our federated approach demonstrated the feasibility and power of harmonizing heterogeneous EHR data from multiple international healthcare systems to rapidly conduct large-scale studies to characterize how COVID-19 clinical trajectories evolve.


 Citation

Please cite as:

Weber GM, Zhang HG, L'Yi S, Bonzel CL, Hong C, Avillach P, Gutiérrez-Sacristán A, Palmer NP, Tan AL, Wang X, Yuan W, Gehlenborg N, Alloni A, Amendola DF, Bellasi A, Bellazzi R, Beraghi M, Bucalo M, Chiovato L, Cho K, Dagliati A, Estiri H, Follett RW, García-Barrio N, Hanauer DA, Henderson DW, Ho YL, Holmes JH, Hutch MR, Kavuluru R, Kirchoff K, Klann JG, Krishnamurthy AK, Le TT, Liu M, Loh NHW, Lozano-Zahonero S, Luo Y, Maidlow S, Makoudjou A, Malovini A, Moal B, Morris M, Mowery DL, Murphy SN, Neuraz A, Ngiam KY, Okoshi MP, Omenn GS, Patel LP, Pedrera-Jiménez M, Prudente RA, Samayamuthu MJ, Sanz J, Schriver ER, Schubert P, Serrano-Balazote P, Tan BW, Tanni SE, Tibollo V, Visweswaran S, Wagholikar KB, Xia Z, Zoeller D, The Consortium For Clinical Characterization Of COVID-19 By EHR (4CE) , Kohane IS, Cai T, South AM, Brat GA

International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study

J Med Internet Res 2021;23(10):e31400

DOI: 10.2196/31400

PMID: 34533459

PMCID: 8510151

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.